AbbVie announces $195M investment to expand API manufacturing in U.S.

AbbVie (ABBV) announced a $195M investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient production in the U.S. This expansion is part of AbbVie’s previously announced commitment to invest more than $10B of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity. Active pharmaceutical ingredient manufacturing is a complex and multi-step process that involves producing the active components responsible for the therapeutic effects of medications. The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the U.S. supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines. “Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.” Construction of the new North Chicago API facility will begin in fall 2025, with the site projected to be fully operational in 2027. The facility will expand AbbVie’s existing U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites and thousands of additional jobs at suppliers around the U.S.